ASN-004 is under clinical development by Asana BioSciences and currently in Phase I for Head And Neck Cancer Squamous Cell Carcinoma. According to GlobalData, Phase I drugs for Head And Neck Cancer Squamous Cell Carcinoma have an 80% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how ASN-004’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
ASN-004 is under development for the treatment of solid tumors including breast cancer, colorectal cancer, non-small cell lung cancer, ovarian cancer, and head and neck squamous cell carcinoma. The drug candidate is an antibody-drug conjugate (ADC) which acts by targeting 5T4-oncofetal glycoprotein. It is developed based on fleximer linker (Dolaflexin) technology.
It was under development for the treatment of gastric cancer and cervical epidermoid tumor.
Asana BioSciences overview
Asana BioSciences (Asana) is a clinical-stage biopharmaceutical company that offers discovery and development of novel targeted investigational medicines. The company’s early-stage drug candidates include ASN001, ASN002, ASN003, ASN004, ASN005 and others. It develops drugs in therapeutic areas of oncology, urology, inflammation, respirator and, pain management, among others. Asana’s lead candidates are in phase I and II clinical studies and other molecules at late stages of preclinical development. The company works in collaboration with research institutions and biotechnology companies. Asana is headquartered in Lawrenceville, New Jersey, the US
For a complete picture of ASN-004’s drug-specific PTSR and LoA scores, buy the report here.